C-4VXPBetalin Therapeutics
stem cells, tissue engineering, beta cells
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-4VXP
C-4VXPC-4VXPstem cells, tissue engineering, beta cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
%PDF-1.7 %���� 7021 0 obj > endobj 7040 0 obj >/Filter/FlateDecode/ID[ ]/Index[7021 46]/Info 7020 0 R/Length 101/Prev 11412655/Root 7022 0 R/Size 7067/Type/XRef/W[1 2 1]>>stream h�bbd``b`?${�s��Hp���m �#��P"+�W����p�@�W��� � ��p;�P���(��b``�3��Y�K���Y }�] endstream endobj startxref 0 %%EOF 7065 0 obj >stream h��U�oRW �^^b�z/�ZZ�RJ���"�6 �J��������a�j�V��Ze��W�M�N��U�YuY�mJ�ĩi�M�ͷ$3���0 {���g� vr�9�����~�� �9�@ ,�Hx�H�qP���Ț��k�߾R*�/�]Q^]V3s%# ��F�P��e9ɻ9��18�p�b�e�x��{�I��M�Ȕ��VOn�Fr«�nf�.r�����_�[�ôC��Ҏx��5w�PY�X�����ymäc�{u�a�Gi���~�-;��� �����] �11�t�#���j … ��~>��(��ٽ�/�| ���,y�r�%�'|�)�B-G�0�Fo� endstream endobj 7036 0 obj >stream application/postscript Andrea Kompauer PFL_wb_V2_4C.eps Adobe Illustrator CS3 2009-03-25T09:12:04+01:00 2009-03-25T09:12:04+01:00 2009-03-25T09:12:04+01:00 uuid:57097856AF1ADE119BE3FB8B6A9BD91C uuid:58097856AF1ADE119BE3FB8B6A9BD91C converted from application/postscript to application/vnd.adobe.illustrator 1 False False 169.999959 169.999959 Millimeters Cyan Magenta Standard-Farbfeldgruppe 0 Weiß C … wDDuUo�C������uE/���h��/�9]5ݱ. ���� Pp� endstream endobj 237 0 obj >stream application/pdf Vienna Logo Adobe Illustrator CS4 2010-10-18T16:22:02+02:00 2014-12-16T17:18:41+01:00 2014-12-16T17:18:41+01:00 proof:pdf uuid:5D20892493BFDB11914A8590D31508C8 xmp.did:F77F117407206811A093E482EFD8B270 uuid:9f2b81b0-1d82-614c-b1f3-745f3bffa228 converted from application/pdf to <unknown> saved xmp.iid:D27F11740720681191099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator … 099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator CS4 / converted from application/pdf to <unknown> converted from application/pdf to <unknown> saved xmp.iid:F97F1174072068118D4ED246B3ADB1C6 2008-05-15T16:23:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:FA7F1174072068118D4ED246B3ADB1C6 2008-05-15T17:10:45-07:00 Adobe Illustrator CS4 / saved xmp.iid:EF7F117407206811A46CA4519D24356B 2008-05-15T22:53:33-07:00 Adobe Illustrator CS4 / saved xmp.iid:F07F117407 … DDFD38D0CF24DD 2008-05-16T10:35:43-07:00 Adobe Illustrator CS4 / converted from application/pdf to <unknown> saved xmp.iid:F97F117407206811BDDDFD38D0CF24DD 2008-05-16T10:40:59-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to <unknown> saved xmp.iid:FA7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:26:55-0
Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030 Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia … chnologies, providing information on their potential usability across different application areas. Further, the chapter features a discussion on the key growth drivers and road blocks related to cell encapsulation technologies and their use in treating various chronic conditions. Chapter 4 includes information on more than 40 encapsulated cell therapies and affiliated technologies that are currently being developed by industry players for treating different chronic conditions … eportlinker.com/p05775823/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001 SOURCE Reportlinker Related Links http://www.reportlinker.com 21 % more press release views with Request a Demo × Modal … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Other news to note + | Bioworld | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market
%PDF-1.7 %���� 17655 0 obj >stream h��Xmo�6�+��|�(��D�ǎ�� �l �j��0�,uk���N$M�/� .Zх�R>��Eͤ�����\}��-�X E9x!�$_�շ��rY����=����dw���$� ���j~�D�i�)��+�[o�yE�mDi�&���p�� �iS,eB&���[A��|k����D�t0�d�f�I7�(=-�令�h��*C��g������z� �윏 Ap�����jӇ�d��93&Ҡ�8�sP ���� ��'|R���E5��_荗y]�ݡ u�� ��pU��yRn�f��o �nVT� ������Z��O ����KA��W�ϛ��9M �/)�S'%�Z3 ���b��f ($��7����{���і��Ɉ�q 5����>Hi2��9�2��g���$�C��Ne��6�FA���n ����;���@e ���� ~'���"� � $_ ����S)��6Ǒ� ���?������Ge��j=Q'c�� �^� } �B\��!I�z�87X�b/$��qH�� ���A$wdv)3'RA�`�/�;HJ�. �]@R�� u����OK��i���� .�� $|��� … V� �> �8� �u�P*� � ����C��A9�i�o �;b1蘮��5��yl�-{[{��+�p����ʣ�t� Ϭ�C�� �5۵rFp=+�+��x1���?۷Y���c4��O�Ft�ה�M_x@ ��5�~6���QHtx�X��gI �1'���B��� |A�t���WHѭ�k ��'�Q�3l� (鞣��F �-|A���-{i �����1�>���Ee �#����1� ���_hhۓFӕ���T ҵ(� K�;@�t��*�Am K![U'j��zU��h� ��b ;���:�U����$��m�b�Š����3:[3�n2#���u�~ �f�Ěv��_��t�X�����2���;�u�ǚ���� �}�:�T��t�Тi���� �{z{�θx�=?ÿ�KOB��{Y��!IY��v�w��Z^*����,uM_Y3L�H�M9 e�mǩ>����m1��i�eI���ӵ54="5e].�T��?�g�"K�|� … �I��?ɟ�'��$�O��� �?�O�'�I��?ɟ�'��$�O����?���g�Y��?˟�g�3�,ƿ�yƿ >stream application/pdf aflac_one_day_pay_logo_4cp 2015-05-04T12:31:19-04:00 2015-05-04T12:31:19-04:00 2015-05-04T12:31:19-04:00 Adobe Illustrator CC 2014 (Macintosh) uuid:20605ad9-6c75-2248-ac2b-7fc74cf91696 xmp.did:6a0f3124-d074-4d8c-bc08-6977962f7983 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:c13d2ae7-a2cf-7846-8824-52e31c2501b2 xmp.did:977a9835-af0a-4b53-9fc1-255a39455207 uuid:5D20892493BFDB … 3C 2014-10-20T17:30:42-04:00 Adobe Illustrator CS6 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to … t to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:29126ef2-d9ed-40be-aa4a-f1e77e2fbe44 2015-01-29T11:14:59-08:00 Adobe Illustrator CC 2014 (Macintosh) / saved xmp.iid:e441c70b-d904-47bc-b175-c75fc3ba8860 2015-01-29T11:16:33-08:00 Adobe Illustrator CC 2014 (Macintosh) /
MS Pharma successfully launched its first generic Linagliptin in the Jordanian market, Diabeten (Linagliptin) and Diabeten M (Linagliptin/Metformin), during a symposium that gathered leading experts to share insights on antidiabetic treatments. From endocrinologists to cardiologists, the event sparked informative discussions and highlighted our dedication to advancing healthcare options. | MS Pharma
%PDF-1.3 %���� 366 0 obj > endobj xref 366 31 0000000016 00000 n 0000000989 00000 n 0000001065 00000 n 0000001749 00000 n 0000002000 00000 n 0000002023 00000 n 0000002162 00000 n 0000002185 00000 n 0000003368 00000 n 0000004606 00000 n 0000004797 00000 n 0000004819 00000 n 0000005891 00000 n 0000005913 00000 n 0000006845 00000 n 0000006867 00000 n 0000007891 00000 n 0000007914 00000 n 0000009065 00000 n 0000009087 00000 n 0000010160 00000 n 0000010183 00000 n 0000011331 00000 n 0000011621 00000 n 0000011644 00000 n 0000012777 00000 n 0000012835 00000 n 0000013695 00000 n 0000014518 00000 n 000
🚀 BDUK Therapeutics LTD. is advancing toward first-in-human Phase 1 loco-regional therapy for liver cancer trial, with strong European Commission validation and a clear value-creation path. BDUK Therapeutics LTD. is developing a dual-drug, controlled-release therapy using PLGA biodegradable microspheres to deliver embedded chemotherapy locally at the tumor site. The objective is straightforward: higher efficacy with lower systemic exposure, addressing the core limitations of current loco-regional approaches. The technology behind BDUK Therapeutics LTD. was created by Prof. Ofra Benny from HUJ … cellence after evaluation by an international panel of independent experts. The proposal was recognized as high quality in a highly competitive EIC Transition process and was recommended for alternative funding only due to budget constraints. 🧬 Investment thesis BDUK is engineering clinically established components into an optimized loco-regional therapy for HCC, designed to improve local drug performance while materially de-risking safety and development. 📌 Why now • Large … cellence after evaluation by an international panel of independent experts. The proposal was recognized as high quality in a highly competitive EIC Transition process and was recommended for alternative funding only due to budget constraints. Investment thesis BDUK is engineering clinically established components into an optimized loco-regional therapy for HCC, designed to improve local drug performance while materially de-risking safety and development. Why now • Large marke
Instagram Instagram Log In Sign Up Close Never miss a post from cannmedevents Sign up for Instagram to stay in the loop. Sign up Log in cannmedevents and medicinal.genomics More options cannmedevents 56w NEW CannMed Coffee Talk, we discuss The Science of Cann*bis Safety Testing! Morgan Keefer is the Senior Accreditation Officer at A2LA where she works with and assesses cann*bis testing laboratories across the United States. Since joining A2LA, Morgan has presented about Laboratory Shopping, Proficiency Testing, and Microbial Testing in the cann*bis industry at Cann*bis Science Conference, A2LA
10 Israeli Advances Helping Diabetics Prevent and Manage their Illness | Jewish Federation of the Lehigh Valley Jewish Federation of the Lehigh Valley Menu Donate Annual Campaign for Jewish Needs Tribute Cards & Trees Emergency Campaign for Israel Connect Log In Search Donate Annual Campaign for Jewish Needs Tribute Cards & Trees Emergency Campaign for Israel Connect Log In About Us Who We Are Board & Staff Directory Annual Report & Financials Glossary of Federation Terms Planning & Allocations Process Career Center Pomegranate Pin Licensing & Marketing Contact Us Upcoming Events Commu … ncy Campaigns Emergency Campaign Operation Rising Lion Planned Giving Endowment Fund Donations LIFE & LEGACY Tribute Cards & Trees Youth Tzedakah EITC Get Involved Women's Philanthropy Dignity Grows Pomegranate Pin Program NextGen Maimonides Society Maimonides Society Directory Maimonides Perpetual Annual Campaign Endowment Community Relations Council Report an Incident Jewish News & Views Take Action Connect with Israel Partnership2Gether Community Shaliach Missions & Travel … s completed multiple Phase II clinical trials under an Investigational New Drug application with the US Food and Drug Administration. Oramed CEO Nadav Kidron participated in the 2017 Disruptive Growth Company Showcase NYC Conference in September in New York City. 2. DarioHealth Dario makes a personalized, pocket-sized, all-in-one glucose meter coupled with a real-time mobile app to track, monitor and manage diabetes from a smartphone. Last month, this Caesarea-based digital h
Start-Up Area and Competition – Biomed 2017 Skip to content Search for: 16 th National Life Sciences & Technology Week May 23 - 25, 2017 | David InterContinental Tel Aviv, Israel Homepage Previous Events Gallery Conference COMMITTEES Welcome Letter Call for Company Presentations Start-Up Area and Competition Program-at-a-Glance Program Tuesday May 23 Program Wednesday, May 24 Program Thursday, May 25 Meet The Speakers (Click on picture to view bio) Instructions for Oral Presentations Exhibition & Sponsorship Start-Up Area and Competition Sponsors & Exhibitors How To Exhibit … track for that day. In addition to your stand, you will have the opportunity to apply to participate in the Start-up Area Competition. The ten finalists who will give an oral presentation as part of the conference, will enjoy additional exposure and stand a chance win the Start-up Area Competition. These ten finalists will be asked to submit an abstract. HOW TO PARTICIPATE: As a first step, companies are kindly requested to fill the online form via the "Register Here" button. … es are kindly requested to fill the online form via the "Register Here" button. Deadline to register: April 10, 2017 The registered companies will be then reviewed by the Start-up Area Committee who will select the companies to participate as exhibitors in the Start-up Area. Participation Tariff: 1500 NIS * Price is for 1 day of the exhibition, the date dependent on the daily Conference Tracks. Companies who are selected to participate in the Startup Pavilion will receive the
%PDF-1.6 %���� 25398 0 obj > endobj 25417 0 obj >/Filter/FlateDecode/ID[ ]/Index[25398 30]/Info 25397 0 R/Length 97/Prev 1617726/Root 25399 0 R/Size 25428/Type/XRef/W[1 3 1]>>stream h�bbd```b``������-�d���A$�F�\"Y%��`��| 9fw�U�I'� �u/�d| R��I&F�� q� >stream h��UmL[U~�m)]���H;����N�V\mY��f���6+&����l. ��PV�A ]t���?�� �t��Xu2L�m��uKq$D��s�l1��'眾�s��y�=�9h�σ@� 5aih0 ���/I�Wtv�gѭ�� ���ϰc=K5%������ ��Y}�}�\Yh�Y�&�m��eG��elkeGG�˕[y/d��麇��?R-�n��喎J��ڣ%p_ �T�2�|M�?t��xx��*Gru��|�O-�mbu 5;犛*���u/��|�6�Ŕe]"n���ͶN������s1�5qs��.��0'�bOM�]̺/���W�3;�Zduslͩ����ɽ��?ŝ7� … 71eb57-ebdb-4c50-820e-a80ec928f081 uuid:20ffcf93-6fcd-4dd0-9808-388f2e2e8898 46 application/pdf Felicia Chambers Adobe PDF Library 24.1.124 D:20240326225506 endstream endobj 491 0 obj >stream hޜ��j�1�_e��4���&�c҅ !Mb���G� )g����o%�f�9� A�!�w*(m�(�\%��*K 6T�d>�J��&�sMj�Z�Ǹ1�qM�L���p*�e���,М�,��|V$�C6A�O�.m���AE�F�^��UY�f}3'��CլB�i�_�������� /}E�p����� Q��*;����~ ��ߎϷ� �g]�5�/i��Tq����� x� �.��)�Q�k� ά >stream h�d�ˊ�@��W��Bө�#3� 7*#��K��&%e��� … 71eb57-ebdb-4c50-820e-a80ec928f081 uuid:2f427d17-b419-4157-87ed-235e9f8a054b 46 application/pdf Felicia Chambers Adobe PDF Library 24.1.124 D:20240326225506 endstream endobj 25428 0 obj > endobj 25429 0 obj > endobj 25430 0 obj > endobj 25431 0 obj > endobj 25432 0 obj > endobj 25433 0 obj > endobj 25434 0 obj > endobj 25435 0 obj > endobj 25436 0 obj > endobj 25437 0 obj > endobj 25438 0 obj > endobj 25439 0 obj > endobj 25440 0 obj > endobj 25441 0 obj > endobj 25442 0 obj
GoforIsrael Investment Conference Home About Us Agenda Events Past Selected Events Why Attend? Contact Our News Follow Follow Go for Israel Investment Conference – Miami 2026 December 14, 2026 — Fontainebleau Hotel, Miami Beach Connecting Between Leading Global Investors and Israel’s Most Innovative Technology Companies REGISTER NOW Upcoming Events About Us The conference connects Israeli tech and life sciences companies with leading international investors, corporations, and financial institutions to create investment opportunities, business development, and strategic partnership … nder the vision of its accomplished organizer, Cukierman & Co. and Catalyst Fund has historically been responsible for catalyzing some of the major connections between Israeli Innovation and global investors.” ARIEL SHARON Former Prime Minister of Israel “The initiators of this important conference, you, Roger Cukierman and your son, Edouard, the CEO of Cukierman & Co. are providing a tangible expression of that same determination and dedication to act – … ng Events Past Conferences Why Attend? Contact Our News For more information to apply as a Speaker or a Sponsor for our next conference please contact: Aron Pacifici Marketing Manager Cukierman & Co. Investment House +972 58-785-6689 [email protected] © 2025 All rights reserved | Go f or Israel.com Powered by © 2024 All rights reserved | Go f or Israel.com Powered by
Instagram Instagram Log In Sign Up Close Never miss a post from mumswhocode Sign up for Instagram to stay in the loop. Sign up Log in Tags moniepointng mumswhocode • Follow More options mumswhocode 16w We are incredibly proud to announce @moniepointng as an Official Sponsor for the MumsWhoCode #IWD2026 Conference! 🚀💙 Moniepoint is at the absolute forefront of driving digital and financial inclusion across Africa. By throwing their weight behind the “Give to Gain” vision, they are actively ensuring that mothers have the resources, access, and support needed to build thriving careers as techie
O... - BIRD Foundation - Israel-U.S. Binational Industrial R&D Facebook Log In BIRD Foundation - Israel-U.S. Binational Industrial R&D's Post BIRD Foundation - Israel-U.S. Binational Industrial R&D January 27 · Shared with Public Over the past month, BIRD’s West Coast Director Anat Bujanover, has been on the move - building connections across California and Nevada in sectors where innovation is pushing toward commercialization. From almond orchards to AI showcases and healthcare summits, her recent engagements reflect the diversity and depth of BIRD's reach. Across each o
%PDF-1.6 %���� 6172 0 obj > endobj 6314 0 obj >/Filter/FlateDecode/ID[ ]/Index[6172 152]/Info 6171 0 R/Length 333/Prev 15350662/Root 6173 0 R/Size 6324/Type/XRef/W[1 3 1]>>stream hތ��JA�g&3� &H �`�`e#�B,|��j�����`aai#��6V�V�D��ltq��s�q��4 �s��UR��PB)(���P���C��W���rmv�.�U��`�v��t v� �m�Cv Z��&&�/x�Ʉ1!mR=�#�����I��rL~�O�$o�*���jTt�����k��Γ�dĭn0� �C�~��̭�Ѧ�o�)����o����t�� #I�KЗ�z��f�ԙ >stream hU{Tw�3�IB�@�u� �� �(P CD*&W �;��[�j2���$msJ�M�q����:�J��-�E9��̘���Ō$MAhH9�~a� /'��n,i�Jk9��7�۶��lo���&���Zd�J�΄��n��o�^�Wp�4�>I��dU�7��Ȏ��� ^�����/B7~w�?�s�����nt,K �"�3� … a��Ϗ ��a��o�Ͳ�(f�.�W��O.���a\�� ������` endstream endobj 3728 0 obj >stream application/pdf Merc Ad copy 2023-10-12T22:20:24+03:00 2023-10-12T22:20:24+03:00 2023-10-12T10:01:47+03:00 Adobe Illustrator 27.9 (Macintosh) uuid:7e0e9671-8f3c-4413-9c19-5848a52e68b2 xmp.did:9de8084f-6102-498a-8ce1-1afcdab694bd uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:8b23cb02-3fd1-9e42-b862-397aed615356 xmp.did:3c31e112-acc1-4fa0-afe7-43d9f5e5cec1 uuid:5D20892493BFDB11914A8590D31508C … ���{�i��`=�r_��i LT�!r���R�{� >stream Acrobat Distiller 9.5.5 (Macintosh) application/pdf zeev ITA_A4_AD_PRINT 2024-02-19T13:37:26+02:00 FreeHand 9: LaserWriter 8 8.7.3 2024-02-19T13:37:26+02:00 uuid:cd8edd12-935b-42d5-a035-039639c9a4bb uuid:47816492-6a4e-4398-a66c-07a97ba8be2a endstream endobj 3746 0 obj >stream H�TRMk�0�� ��B����&V�@H(�P��B�Akk���d$m���� �t�z3o�|� ����� ��� NJ����L�ɌfJ�S�����?Ã� ʳ�1�mv*oT~�� �@�g�d[�)`=���(}��? �����!�^"�@��:���( d��# � … 050ec67a6a xmp.id:9424c24b-29cd-d84f-968c-bd70360fd98c proof:pdf converted from application/x-indesign to application/pdf Adobe InDesign 19.1 (Windows) / 2024-01-31T15:11:25+02:00 xmp.iid:e5cd9389-c41f-fc4b-8c37-535374843427 xmp.did:635c856b-3523-5a41-b985-d2050ec67a6a xmp.did:635c856b-3523-5a41-b985-d2050ec67a6a default application/pdf Adobe PDF Library 17.0 False endstream endobj 4721 0 obj >stream x콉�,�Y�?�̜mνW�jI^$o�ly�ɫ�/x���I�,� �-�%�-�IX�$$���� 0��16�����{� … PScript5.dll Version 5.2.2 2022-11-03T10:07:21+02:00 2022-11-03T10:07:21+02:00 application/pdf biolight a4.FH10 User Acrobat Distiller 19.0 (Windows) uuid:87c2a686-f670-46c8-b38b-44b09a86ac8c uuid:644a994f-7393-4177-abe9-41f16ea66602 endstream endobj 4827 0 obj >stream x���s iz��(�|�{�Ȧ�$@A� H�*, f��BW�f��5�݃�:�j�^H�1��m�GZ�}��aN��}�q�=n��
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Massachusetts is where big... - Governor Maura Healey Facebook Log In Governor Maura Healey's Post Governor Maura Healey Verified account April 17 · Shared with Public Massachusetts is where big breakthroughs happen—and ARC Landing connects us to @sheba.medical.center’s network of 120+ startups in Israel and worldwide that are shaping the future of health care. Together, we’re accelerating innovation, creating jobs, and delivering life-saving cures and treatments for people around the world. All reactions: 405 512 comments 14 shares Like Comment Most relevant David Anthony Waiting for thi
Coming on July 3rd: #Diabetes... - Galilee Medical Center Facebook Log In Galilee Medical Center's Post Galilee Medical Center June 26, 2019 · Shared with Public Coming on July 3rd: #Diabetes Conference for patients and their families. For information and to register, call: 04-9107558. The sixth conference, co-sponsored by Galilee Medical Center and the Israeli Diabetes Association will take place next week at the Engel Health Education Center at GMC under the auspices of Dr.Masad Barhoum, head of the medical center, and Dr. Motti Perlmutter, the head of the Israeli Diabetes Association,
David E.R. Sutherland Diabetes Symposium - University of Minnesota Continuing Professional Development - Continuing Education (CE) Professor Emeritus David E. R. Sutherland, MD, PhD, (1940-2025) served as the Chief of the <a href="https://med.umn.edu/surgery/divisions/transplantation" target="_blank" title="">Division of Transplantation</a> from 1995-2009 and directed the <a href="https://med.umn.edu/surgery/research/schulze-diabetes-institute" title="">Schulze Diabetes Institute</a> from 1994-2013. He is remembered as the father of … /p><p>Crowning his distinguished career, he received the prestigious Medawar Prize in 2012 followed by the ASA Medallion for Scientific Achievement in 2016. Equally, if not more importantly, David Sutherland was a compassionate physician who shared deeply in his patients' struggles and triumphs. He performed thousands of transplants that freed many from insulin and dialysis for life. A humble and widely respected surgeon, he was a beloved mentor who trained transplant … tected] | 612-626-7600 Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … (2002). Crowning his distinguished career, he received the prestigious Medawar Prize in 2012 followed by the ASA Medallion for Scientific Achievement in 2016. Equally, if not more importantly, David Sutherland was a compassionate physician who shared deeply in his patients' struggles and triumphs. He performed thousands of transplants that freed many from insulin and dialysis for life. A humble and widely respected surgeon, he was a beloved mentor who trained transplant surg … surgical and immunosuppressive management of patients with diabetes Discuss the application of kidney transplantation in the treatment of diabetes. Describe the role of total pancreatectomy and islet autotransplantation in treating patients with chronic pancreatitis. Outline the differences between islet transplantation and pancreas transplant, i
Revolutionizing diabetes treatment: progress on micro pancreas | The Jerusalem Post CONFERENCES ISRAEL NEWS WORLD NEWS MIDDLE EAST BUSINESS & INNOVATION DEFENSE & TECH OPINION JP STORE Login Login Subscribe JPOST DIGITAL LIBRARY HOME PAGE THE JERUSALEM REPORT DEFENSE & TECH OPINION BUSINESS & INNOVATION JERUSALEM POST EN ESPANOL REAL ESTATE LISTINGS ALIYAH JERUSALEM POST CONFERENCE PREMIUM JP STORE Categories ISRAEL NEWS WORLD NEWS MIDDLE EAST US POLITICS DIASPORA OPINION PODCAST JUDAISM KABBALAH CHRISTIAN WORLD HEALTH & WELLNESS SCIENCE LAW ARCHAEOLOGY OMG ENVIRONMENT &
Extracellular Matrix-Guided Islet Cell Transplantation Improves Glycemic Control | Betalin Therapeutics Ltd. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking … ch source of growth factors and immunomodulatory ligands ✅ Established clinical application in ophthalmic and dermatological settings ✅ Broad potential as a human-derived culture supplement ✅ Optional pooling to help reduce inter-donor variability Anthony Nolan has been supplying cord material and its valuable by-products for over 15 years, supporting both clinical use and translational research. If your work involves cord plasma for stem cell support, regenerative therapies,
%PDF-1.5 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S>> endobj 4 0 obj > stream x��[mo�8� �� �E�ߩ�C���v{W�mš����F�g�-�O�o����[r�D:�$j�g�8���˫ӓ�_ ��̲����R�'���j�2ǍdW�@��c���I�n��WO�NO>&l� v��ӓ0�OOޝ�\^ �-�4D��K9ćW���X��A ˝`Nr���8"�M� ^�3����� ��{�)&Ou�a��}��#���{?�o�Ԥ\ �R����H��f �w�by7�I�Y]����T��Ե�d)OM��������jA+�Q��u?s�w��bt@����W����, ����g��5Z���lh��t�8��(H�Yn�n �a+j� ���m���-*`ʟo��,m�w]F&�� #)VqP��*���A��dR� k]�r7�u�C� ��ѥ��@�.+SIm��o��- … mageC]/XObject >>>/Tabs/S/Type/Page>> endobj 44 0 obj > endobj 57 0 obj >stream application/pdf Sharmala Manickum 2022-10-04T09:32:20+02:00 Microsoft® Word 2013 2022-10-04T09:37:06+02:00 2022-10-04T09:37:06+02:00 Microsoft® Word 2013 uuid:f3b36370-a9cc-4eb7-b204-84a28eeb9f0f uuid:2294255b-ae9c-4f9d-a312-d7203d781335 endstream endobj 58 0 obj > endobj 59 0 obj >stream H��W]S�6}ϯУu�(���G�e��I)�Ɲ���I �$1$�B�}Wև�$ �aH��������@�$�(�2�R��P.I�к|��V��#-�7)��~�Pt����"���� � … 90>> startxref 157740 %%EOF 1 0 obj > endobj 44 0 obj > endobj 57 0 obj >stream application/pdf Sharmala Manickum 2022-10-04T09:32:20+02:00 Microsoft® Word 2013 2022-10-04T09:37:46+02:00 2022-10-04T09:37:46+02:00 Microsoft® Word 2013 uuid:f3b36370-a9cc-4eb7-b204-84a28eeb9f0f uuid:ca0eb790-638e-4909-9f23-62c5ee2ab1d1 endstream endobj xref 0 2 0000000000 65535 f 0000158959 00000 n 44 1 0000159069 00000 n 57 1 0000159248 00000 n trailer ]/Prev 157740>> startxref 162633 %%EOF
Betalin Therapeutics - Catalyst Investors' Club Join Catalyst Investor's Club now for exclusive investment opportunities in top-tier startups! Sign up Hi , You're just one step away from unlocking Level 2 level up now! Menu My Profile Investment Opportunities About us Investors FAQ add your company News Contact us Categories GoforIsrael Unicorn AI Mobility Deeptech Clean Tech Med Tech Fintech Cybersecurity Agritech Ocean Tech Foodtech Manufacturing Media Biotech Data Digital Health SaaS Search EN Sign in Sign up Betalin Therapeutics Betalin Therapeutics seeks to eliminate the ne
Betalin Therapeutics wins best biopharma startup award - Globes " /> " /> " /> " /> search G Front News Comment Features MARKET ECONOMY ENERGY HEALTHCARE TECH REAL ESTATE START UPS AEROSPACE & DEFENSE CHEMICALS & PLASTICS FINANCIAL SERVICES MERGERS & ACQUISITIONS POLITICS TELECOMS, MEDIA & MARKETING TOURISM TRANSPORT & INFRASTRUCTURE Front > News Betalin Therapeutics wins best biopharma startup award Betalin Therapeutics Photo PR Enlight raises $2.6b for Arizona solar project Enlight raises $2.6b for Arizona solar project 7 Jun, 2017 13:59 Globes correspondent The Israeli company, which spe … i company, which specializes in tissue engineering for curing diabetes, won the award at the Tel Aviv MIXiii biomed conference. Israeli company Betalin Therapeutics , which specializes in tissue engineering for curing diabetes, has been chosen out as the most innovative biopharma company of the year in the startup competition of the Tel Aviv MIXiii Biomed Conference, Israel’s leading life science industry event. Based in Ramat Gan, Betalin Therapeutics develops the Engi … Advertising Terms of Use Privacy Policy About Support Powered by UI & Design By Application delivery by � Globes. All rights reserved. Twitter Facebook Linkedin RSS Newsletters ����� Israel Business Conference 2018
Cure Diabetes by Injection of Micro Pancreas Cell Therapy | Micro Pancreas | Project | Fact Sheet | H2020 | CORDIS | European Commission Skip to main content (opens in new window) Log in Log in English en Select your language Close CORDIS languages: es español de Deutsch en English fr français it italiano pl polski Machine translation: This is a machine translation provided by the European Commission’s eTranslation service to help you understand this page. Please read the conditions of use . български español čeština dansk Deutsch eesti ελληνικά français Gaeilge hrvatski italiano latviešu liet … porting Results Fact Sheet Reporting Results Project Information Micro Pancreas Grant agreement ID: 959049 (opens in new window) Project website This website may no longer be available or may not contain the original content. Please confirm that you want to visit {{ url }} Open URL Cancel DOI Each project (from H2020 onwards) is attributed a Digital Object Identifier (DOI) 10.3030/959049 Project closed EC signature date 19 August 2020 Start date 1 September 2020 End date 29 F … he sum of the EU contributions of all participants in a project is equal to the grant amount. € 2 452 625,00 2 452 625,00 1 051 125,00 Coordinated by BETALIN THERAPEUTICS LTD Israel Project description DE EN ES FR IT PL Novel micro-organ to restore natural insulin production and regulate blood glucose levels Lifelong insulin administration is the only therapeutic approach for diabetes patients to prevent the disease's significant and often life-threatening complications. Howe … nto topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project. EIC-SMEInst-2018-2020 - SME instrument See all projects funded under this topic Funding Scheme Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify … E instrument phase 2 See all projects funded under this funding scheme Call for proposal Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding. (opens in new window) H2020-EIC-SMEInst-2018-2020 See all projects funded under this call Coordinator BETALIN THERAPEUTICS LTD Net EU contribution Net EU fina
Betalin Therapeutics Wins Startup Competition at MIXiii Biomed 2017 Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Ga … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Betalin Therapeutics Wins Startup Competition At Mixiii Biomed 2017 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Betalin Therapeutics Wins Startup Competition At Mixiii Biomed 2017 June 6, 2017 | 4 min read Twitter LinkedIn Facebook Email Print TEL AVIV, Israel , June 5, 2017 /PRNewswire/ -- Betalin Therapeutics , a biotech company specializing in tissue engineering for curing diabetes, announced today that it was chosen out of do … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Possible diabetes cure from HU research moves closer to clinical trials - The Canadian Friends of Hebrew University Skip to content Who We Are Expand CFHU Expand About CFHU Leadership Contact Us Subscribe Hebrew U Expand About Hebrew U Faculties & Centres What We Do Expand HUJI Forum International Partnerships Spotlight on Philanthropy Spotlight on The Scholars CFHU & HU Publications News & Events Expand 100th Anniversary Hebrew U HUJI Forum HU News CFHU News Events Expand Upcoming Events Past Events Multimedia Expand Videos Photo Galleries Webinars Students & Alumni Expand … udying at Hebrew U Expand Why Study at Hebrew U? Programs of Study Scholarships Scholarship Recipients 2025-2026 Scholarship Recipients 2024 Scholarship Recipients 2023 Scholarship Recipients 2022 Transcript Alumni Expand Alumni We Love Spotlight CFHU Alumni Ways To Give Search Donate Now Who We Are Expand CFHU Expand About CFHU Leadership Contact Us Subscribe Hebrew U Expand About Hebrew U Faculties & Centres What We Do Expand HUJI Forum International Partnerships Spotl … udying at Hebrew U Expand Why Study at Hebrew U? Programs of Study Scholarships Scholarship Recipients 2025-2026 Scholarship Recipients 2024 Scholarship Recipients 2023 Scholarship Recipients 2022 Transcript Alumni Expand Alumni We Love Spotlight CFHU Alumni Ways To Give Donate Now Toggle Menu Featured Story , News Possible diabetes cure from HU research moves closer to clinical trials Posted on: November 12, 2019 Israel’s Betalin Therapeutics is developing an artificial panc … ber 14, Israeli startup Betalin Therapeutics announced that it is beginning the application process for clinical trials of its revolutionary artificial pancreas. Betalin’s Engineered Micro Pancreas (EMP) aims to free patients suffering from the most severe types of diabetes from constantly monitoring blood-sugar levels and injecting insulin. About 160 million people are insulin dependent. The road to an Israeli-made artificial pancreas has been a decade in the making. When IS … king on making its own. Betalin was recently awarded a binational collaboration grant by the Israel Innovation Authority and the Italian government to work with beta cell expert and transplant researcher Prof. Lorenzo Piemonti. Years of clinical trials ahead Diabetes patients will have to wait a few years before the technology is fully tested. So
Betalin Therapeutics' Engineered Micro Pancreas boosts diabetes treatment | HORDUS.ai posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join o
Bio-technology firm chooses Nexus as UK base to develop revolutionary diabetes treatment - Nexus Skip to main content Menu About us About us Our Members Our Partners Venue Hire Membership Nexus membership Workspace Case Studies News & Events Events News & Opinion Contact Us Search Home › News › Bio-technology firm chooses Nexus as UK base to develop revolutionary diabetes treatment Bio-technology firm chooses Nexus as UK base to develop revolutionary diabetes treatment An award-winning international bio-technology company has chosen Nexus to take its revolutionary diabetes treatment … g further optimised with the support of an advisory board, which includes Nobel Prize winners Professor Sidney Altman and Professor Arieh Warshel and the company is now raising capital to further develop their ground-breaking technology, which could radically improve the lives of 170 million people worldwide. “The move to Nexus is a major step forward for us,” said Dr Nikolai Kunicher, CEO of Betalin Therapeutics. “I visited Nexus last year and was extremely impressed with th … k an exciting milestone with the introduction of the brand-new Nexus Innovation Award - accompanied by prize funding for the top three businesses, and a testament to the strength of the entrepreneurial talent coming through the programme. Read article Blog | News FCA visits Nexus to discuss innovation, AI and the future of financial services Nexus welcomed a delegation from the Financial Conduct Authority (FCA) for a visit focused on innovation, regulation and the rapidly cha
Betalin Therapeutics receives EU equity investment for its alternative insulin therapy - CTech 24/7 Buzz Startups VC Finance@ Work@ Innovation Opinions by Homepage CTech News Betalin Therapeutics receives EU equity investment for its alternative insulin therapy The Biomed startup seeks to eliminate the need for insulin injections and glucose testing James Spiro 09:52 21.07.21 TAGS: Biomed Biotech Diabetes EIC Insulin Betalin Therapeutics Betalin Therapeutics has announced that it will receive capital from the European Innovation Council (EIC) fund after the fund’s investment committee a … e proud to be among the first technology companies that the European Innovation Fund has decided to invest in,” said CEO Dr. Nikolai Kunicher. “The Fund’s investment is a testament to the EU's confidence in the technology Betalin is developing and its ability to bring a solution for many people suffering from diabetes. The money raised will help to accelerate continuation of the trials until the product’s development is completed.” Betalin Therapeutics CEO Dr. Nikolai Kuniche … he British regulatory authority. Related articles TripleW receives $2.6 million grant from EU for its lactic acid for food waste Technion ranked No. 1 in Europe in Artificial Intelligence NanoVation receives $5.9 million from European Innovation Council Fund for its respiratory monitoring device The EIC was established in June 2020 by the European commission designed to provide startups equity ranging between €0.5 million and €15 million ($588,000 and $17.6 million) with the … create meaningful change. The investment follows a €3.6 million ($4.2 million) grant from the EU’s Horizon 2020 R&D program last year. It is understood that the EIC Fund will receive shares in Betalin Therapeutics, although the amount is currently still being negotiated. Betalin Therapeutics was founded in 2015 and seeks to eliminate the need for insulin injections and glucose testing with its Engineered Micro Pancreas (EMP). Its technology helps create connective tissue
Delicious Peppery Beet Borscht Recipe Blog Podcast For Kids Herbal Board Game Herb Fairies Books Join Herb Mentor Log In Delicious Peppery Beet Borscht Recipe all remedies and recipes cooking with herbs We’ve made it through another holiday season and many people are eager to atone for their holiday indulgences by doing a detox or cleanse. The most popular detox programs often include eating raw and cold foods as well as using cooling and eliminating “detox” herbs. But does eating cold raw foods make sense during the cold winter months? Is winter the ideal time to be purging
Advancing Access to Diabetes Care in Cambodia 🇰🇭 The launch event, organised by Camber Pharmaceuticals, a subsidiary of Hetero, was held at Hyatt Regency Phnom Penh and chaired by Asst. Professor TOUCH Khun. The event witnessed the participation of more than 170 healthcare professionals, reflecting a shared commitment toward improving diabetes management and patient outcomes in Cambodia. The launch event, organized by Camber Pharmaceuticals, a subsidiary of Hetero, was held at Hyatt Regency Phnom Penh and chaired by Asst. Professor TOUCH Khun. The event witnessed the participation of more th
Instagram Instagram Log In Sign Up Close Never miss a post from msmsorg Sign up for Instagram to stay in the loop. Sign up Log in msmsorg • Follow More options msmsorg Edited • 3w A major workforce update. Foreign physicians impacted by recent visa delays can continue practicing in the U.S. following a federal policy reversal. International physicians play a critical role in primary care, especially as physician shortages continue nationwide. #TravelVisa #MSMS Load more comments No comments yet. Start the conversation. Like Comment Share Save May 7 Log in to like or comment. More posts from ms
Instagram Instagram লগ ইন করুন সাইন আপ করুন বন্ধ করুন drennanspecialist-এর কোনো পোস্ট মিস করবেন না নিজেকে আপডেট রাখার জন্য Instagram-এ সাইন আপ করুন। সাইন আপ করুন লগইন করুন drennanspecialist • ফলো করুন আরও বিকল্প drennanspecialist 168সপ্তাহ England Feeder Team Sign MAJOR Sponsorship Deal! The Angling Trust and Drennan International are proud to announce a new four-year sponsorship deal with the England Feeder Team. Led by manager Dean Barlow since 2019, the Feeder team had a solid silver medal in the World Championships in Belgium last October and are currently ranked No.1. The new deal – one o
Congratulations Beta Bionics... - Children with Diabetes Facebook Log In Children with Diabetes's Post Children with Diabetes May 21, 2018 · Shared with Public Congratulations Beta Bionics team! Exciting news. Get a chance to meet the team, that’s making magic happen, and hear all about the updates on the iLet at the Orlando Friends For Life conference. Beta Bionics May 21, 2018 · Shared with Public We are thrilled to share that Beta Bionics received IDE approval from the FDA to begin clinical trials using the iLet Bionic Pancreas System! #iLet #BionicPancreas #BTheChange globenewswire.co
Racheli Ofir of Betalin Therapeutics Podcasts Audiolibros Sobre Podimo Para podcasters Iniciar sesión Prueba gratis Israeli Technology Founders Speak: Conversations with Successful Israeli Hitech and Biotech Entrepreneurs Compartir Israeli Technology Founders Speak: Conversations with Successful Israeli Hitech and Biotech Entrepreneurs Racheli Ofir of Betalin Therapeutics 18 min · 31 de may de 2026 Prueba gratis Descripción Racheli Ofir is the CEO and CTO of Betalin Therapeutics, an Israeli company developing a biological micropancreas that could one day offer a one-time cure for insulin-depen
Racheli Ofir of Betalin Therap… - Israeli Technology Founders Speak: Conversations with Successful Israeli Hitech and Biotech Entrepreneurs - Apple Podcasts Căutare Acasă Noutăți Topuri Căutare 31 mai 19 min Racheli Ofir of Betalin Therapeutics Israeli Technology Founders Speak: Conversations with Successful Israeli Hitech and Biotech Entrepreneurs Redați Racheli Ofir is the CEO and CTO of Betalin Therapeutics, an Israeli company developing a biological micropancreas that could one day offer a one-time cure for insulin-dependent diabetes — replacing the missing pancreatic function with living
Betalin Therapeutics Introduces Novel Approach to Treat Diabetes Results published in Tissue Engineering Part A LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … oth for islets and potentially for stem cell engraftment in future for clinical application.” "We are currently in the midst of a financing round to support clinical studies towards the completion of the first-in-human trial,” added Mr. Doron Birger, Chairman of the Board of Directors, Betalin Therapeutics, and former Chair of the Board of Directors of Given Imaging. “We are fortunate to have in our scientific advisory board two leading figures in the area of cell transplanta … s 10 Posts 9,332 Personalized Medicine through Tissue Engineering 8 Posts 9,036 Application of Microfluidics in Tissue Engineering 6 Posts 1,551 Biomaterials for Organ Regeneration 9 Posts 2,849 Tissue Engineering Strategies for Heart Health 10 Posts 8,387 Show more Show less Explore content categories Career Productivity Finance Soft Skills & Emotional Intelligence Project Management Education Technology Leadership Ecommerce User Experience Recruitment & HR Customer
Israeli firm says micro-pancreas to 'cure' diabetes ready for UK trials | Diabetes | The Guardian Skip to main content Skip to navigation Close dialogue 1 / 1 Next image Previous image Toggle caption Print subscriptions Search jobs Sign in Eur Europe edition UK edition US edition Australia edition International edition The Guardian - Back to home The Guardian News Opinion Sport Culture Lifestyle Show more Hide expanded menu News View all News World news World Cup 2026 UK news Climate crisis Ukraine Environment Science Global development Football Tech Business Obituaries Opinion View all Opinio … micro-pancreas that can “cure” diabetes for millions of people has said it will submit a request next month for human clinical trials in the UK. Betalin Therapeutics said its “bio-artificial” pancreas aims to free patients of the need for insulin injections and blood sugar monitoring. It is designed for people with type 1 diabetes, and those with type 2 diabetes who require insulin. The Jerusalem-based firm told the Guardian it would provide a plan for clinical trials to Brit
Cure Diabetes by Injection of Micro Pancreas Cell Therapy | H2020 | CORDIS | European Commission Skip to main content (opens in new window) Log in Log in English en Select your language Close CORDIS languages: es español de Deutsch en English fr français it italiano pl polski Machine translation: This is a machine translation provided by the European Commission’s eTranslation service to help you understand this page. Please read the conditions of use . български español čeština dansk Deutsch eesti ελληνικά français Gaeilge hrvatski italiano latviešu lietuvių magyar Malti Nederlands polski port … porting Results Fact Sheet Reporting Results Project Information Micro Pancreas Grant agreement ID: 959049 (opens in new window) Project website This website may no longer be available or may not contain the original content. Please confirm that you want to visit {{ url }} Open URL Cancel DOI Each project (from H2020 onwards) is attributed a Digital Object Identifier (DOI) 10.3030/959049 Project closed EC signature date 19 August 2020 Start date 1 September 2020 End date 29 F … he sum of the EU contributions of all participants in a project is equal to the grant amount. € 2 452 625,00 2 452 625,00 1 051 125,00 Coordinated by BETALIN THERAPEUTICS LTD Israel Periodic Reporting for period 2 - Micro Pancreas (Cure Diabetes by Injection of Micro Pancreas Cell Therapy) Reporting period: 2022-03-01 to 2024-02-29 Summary of the context and overall objectives of the project Betalin was founded to promote the development of the EMP as a novel islets’ transpla
Racheli Ofir of Betalin Therapeutics - Israeli Technology Founders Speak: Conversations with Successful Israeli Hitech and Biotech Entrepreneurs | Podcast on Spotify
Israel's Betalin Therapeutics plans IPO to fund diabetes trials | The Jerusalem Post CONFERENCES ISRAEL NEWS WORLD NEWS MIDDLE EAST BUSINESS & INNOVATION DEFENSE & TECH OPINION JP STORE Login Login Subscribe JPOST DIGITAL LIBRARY HOME PAGE THE JERUSALEM REPORT DEFENSE & TECH OPINION BUSINESS & INNOVATION JERUSALEM POST EN ESPANOL REAL ESTATE LISTINGS ALIYAH JERUSALEM POST CONFERENCE PREMIUM JP STORE Categories ISRAEL NEWS WORLD NEWS MIDDLE EAST US POLITICS DIASPORA OPINION PODCAST JUDAISM KABBALAH CHRISTIAN WORLD HEALTH & WELLNESS SCIENCE LAW ARCHAEOLOGY OMG ENVIRONMEN … em Post / Health & Wellness Israel's Betalin Therapeutics plans IPO to fund diabetes trials The company, which is funded by private investors, is looking to raise about $40 million in an IPO in New York or London by the end of next year. Follow us on Google A blood glucose test is done to check sugar levels in a Type 2 Diabetes patient ( photo credit : DARRYL LEJA/NIH/FLICKR ) By REUTERS SEPTEMBER 16, 2020 13:50 Loading... See more on diabetes Follow us on Google Rel
Israeli Technology Founders Speak: Conversations with Successful Israeli Hitech and Biotech Entrepreneurs - Podcast - Apple Podcasts Căutare Acasă Noutăți Topuri Căutare Israeli Technology Founders Speak: Conversations with Successful Israeli Hitech and Biotech Entrepreneurs JMB Davis Ben-David International IP Law Firm 0,0 (0) Tehnologie Actualizată bilunar Podcast by JMB Davis Ben-David International IP Law Firm Episod recent Urmăriți Episoade 31 mai Racheli Ofir of Betalin Therapeutics Racheli Ofir is the CEO and CTO of Betalin Therapeutics, an Israeli company developing a biological microp … to discuss what the Innovation Authority does, how to be in the 25% that get a grant, lessons he’s learned over the years, why Israeli is the startup nation and much more. Do you have a great innovation? We'd love to hear from you. Contact us by going to https://jmbdavis.com/startup/contact. Learn more at https://jmbdavis.com and https://jmbdavis.com/startup. Also available at https://soundcloud.com/jmbdavis/ innovation-authority. Listen to all of the episodes at https://jmb
Biotech – Israel Technology Founders Speak Podcast Conversations with Successful Israeli Hitech and Biotech Entrepeneurs Toggle navigation Home Episodes About Us Contact Us Search Search for: Search Category: Biotech Episode 58: Racheli Ofir of Betalin Therapeutics Posted 4 weeks ago Tagged Racheli Ofir is the CEO and CTO of Betalin Therapeutics, an Israeli company developing a […] https://jmbdavis.com/podcast/episode-player/554/episode-58-racheli-ofir-of-betalin-therapeutics.mp3 Episode 54: Dr Hadas Ziso of EndoCure Posted 5 months ago Tagged Dr. Hadas Ziso is the Co-Founder and
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Betalin Therapeutics - European Innovation Council - European Commission Skip to main content Search Search European Innovation Council Menu Close Menu Back Previous items Next items Home Get funding and support EIC Pathfinder EIC Transition EIC Accelerator STEP Scale Up EIC STEP Scale Up Defence EIC Pre-Accelerator Advanced Innovation Challenges- Pilot EIC Business Acceleration Services See all EIC Fund About the EIC Fund Investment opportunities EIC Fund invested companies EIC Fund Investment Guidelines & Approach Trusted Investor Network EIC Fund Board Advisory Comm … d Board Advisory Committee Members Company Board Representatives Scaleup Europe Fund See all EIC Prizes European Prize for Women Innovators powered by EIC & EIT The European Capital of Innovation Awards Previous EIC Prizes See all Impact EIC Impacts Stories EIC Data Hub EIC portfolios EIC Programme Managers EIC Ambassadors See all EIC Board EIC Summit 2026 Events News Home … EIC Fund EIC Fund portfolio Betalin Therapeutics Betalin Therapeutics Next generation of insulin-p
JLM-BioCity (JBNF-BioMed) | Betalin Therapeutics Grand Reveal VIP Invitation: on July 4th at
C. Lotan / Chief Innovation Officer, Hadassah Medical Organization, Jerusalem Israel, Advanced Valve Therapies 2026 #livemedia | Livemedia.gr
THE RELEVANCE OF INTERNATIONAl HEALTH NEWS TO THE SOLOMON ISLANDS Home About Solomon Islands About Frank Short SI News Wooden Carvings Sponsorship Helping Organizations SIDT Christian Care Centre (CCC) Family Support Centre People with Disabilities Association SINCW Take My Hands Cerebral Palsy Group Solomons Tourism SIVB Contact THE RELEVANCE OF INTERNATIONAl HEALTH NEWS TO THE SOLOMON ISLANDS THE RELEVANCE OF INTERNATIONAl HEALTH NEWS TO THE SOLOMON ISLANDS Posted by : Posted on : 27-Jul-2020 Health matters in the UK and international news media Health related news being covered in the UK an … as that can “cure” diabetes for millions of people has said it will submit a request next month for human clinical trials in the UK. “Betalin Therapeutics said its “bio-artificial” pancreas aims to free patients of the need for insulin injections and blood sugar monitoring. It is designed for people with type 1 type 2 diabetes who require insulin. “The Jerusalem-based firm told the Guardian it would provide a plan for clinical trials to Bri … f the vaccine will work. “When pressed further to provide a timescale for rolling out a vaccine, Ms Bingham said : "The global picture is that I don't think there will be any vaccines before next year. "There will be some early vaccines - if everything goes right - potentially at the end of this year." End of quote : Yours sincerely Frank Short Recently Post Unique Cultural Designs on Custom Clothing: Preserving Heritage The Art of Handcrafted Fashion … Designing Company Delhi All rights reserved. Quick Enquiry Send Enquiry × Submit
Gamida Cell Ltd. - IVC Data & Insights --> --> Recently Updated Analytics Products & Solutions Reports & Insights Free Trial Buy Log In Remember Me Forgot my password Free Trial Free Content Please wait Processing your login information Cancel You're about to hit a 'session timeout' in 5 minutes. Are you still actively using IVC-Online website? Search Go Advanced Search Advanced Search Did you know? Search at IVC-Online works best with strings or words of 3 letters or more. Please try again Gamida Cell Ltd. www.gamida-cell … d half of 2020, and we intend to initiate the submission of a biologics license application (BLA) filing in the fourth quarter of 2020. Indication: High-risk Hematologic Malignancies (Phase III); Indication: Severe Aplastic Anemia (Phase I). GDA-201 Phase I GDA-201 is an innate natural killer (NK) cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. When combined with targeted antibodies, GDA-201 has sho … De abCDe * New investor Investor Type Amount Remarks abC Defghij * Hedge Fund abCDe Purchase price is comprised from Highbridge converting $75m of its existing unsecured convertible senior note into equity in the company plus $30m of new capital from Highbridge on the effective date of the restructuring. Public Offerings Deal Date Type of Offering Exchange Amount Raise Valuation Remarks Apr. 21, 2023 Fifth Public Offering NASDAQ GM abCDe abCDe Dec. … * New investor Investor Type Amount Remarks abC Defghij Venture Capital Fund abCDe abC Defghij Venture Capital Fund abCDe abC Defghij Venture Capital Fund abCDe Continue to hold shares after the IPO abC Defghij Venture Capital Fund abCDe abC Defghij Venture Capital Fund abCDe Led the round abC Defghij Private Equity Fund abCDe abC Defghij Investment Company abCDe abC Defghij High-Tech Company abCDe Buyout Mar. 29, 2017 R&D abCDe abCDe * New investor Inve … * New investor Investor Type Amount Remarks abC Defghij Venture Capital Fund abCDe abC Defghij Venture Capital Fund abCDe abC Defghij Venture Capital Fund abCDe abC Defghij Corporate VC abCDe abC Defghij Holding Company abCDe abC Defghij Investment Company abCDe abC Defghij High-Tech Company abCDe Fourth Round May. 15, 2012 R&D abC
משרות לסטודנטים ולבוגרי מדעי החיים בישראל | Lab Technician Betalin Therapeutics Inc
Breakthrough: Alternative Biological Pancreas for Treating Diabetes Patients - Haaretz Labels o Navigation Account Details Haaretz - back to home page Search Accessibility Current section Haaretz Labels Breakthrough: Alternative Biological Pancreas for Treating Diabetes Patients Betalin Therapeutics, based in Jerusalem, develops a groundbreaking alternative pancreas designed to free diabetes patients from dependence on insulin injections. The pancreas is based on biological tissue scaffold on which insulin-secreting beta cells are implanted. The platform has commercial potential not only in th … ientific advisory board Dr. Racheli Ofir earned her doctorate and post-doctoral fellowship in cell biology at the Technion. She has held senior positions in the pharmaceutical industry for nearly 20 years, playing a leading role in developing innovative pharma products. Before joining Betalin, she worked for 15 years at Pluristem Therapeutics as VP of Research. "Our scientific advisory board includes the world's leading scientists and experts in diabetes," she says. "For exam
Betalin Therapeutics Treats Type 1 Diabetes Skip to navigation Skip to content Search: Home Technology Science Environment Culture News Briefs Betalin Aims To End Insulin Injections By Treating Type 1 Diabetes With Cell Transplants By Alice Menichelli and Lauren Blanchard , NoCamels March 03, 2016 4 minutes Science Baby Diabetes Shot via Frankie Leon/Flickr baby diabetes shot --> Of the 382 million people who have diabetes, only five to 10 percent have Type 1 Diabetes. However, unlike like Type 2 Diabetes, which can be prevented with regular exercise and a healthy diet, Type 1 Diabetes is an a
Betalin Therapeutics Introduces Novel Approach To Treat Diabetes - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Betalin Therapeutics Introduces Novel Approach To Treat Diabetes November 10, 2015 | 6 min read Twitter LinkedIn Facebook Email Print RAMAT GAN, Israel--( BUSINESS WIRE )-- Betalin Therapeutics , a biotech company specializing in tissue engineering for curing diabetes, introduces the Engineered Micro Pancreas (EMP), a n … oth for islets and potentially for stem cell engraftment in future for clinical application.” "We are currently in the midst of a financing round to support clinical studies towards the completion of the first-in-human trial,” added Mr. Doron Birger, Chairman of the Board of Directors, Betalin Therapeutics, and former Chair of the Board of Directors of Given Imaging. “We are fortunate to have in our scientific advisory board two leading figures in the area of cell transplanta … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
About Us – priZm Therapeutics priZm Therapeutics Home PriZmTX About Us MCT8 Deficiency (AHDS) News Careers Contact Clinical Study SRW101 About Us PriZm Therapeutics is a late-stage clinical biotech company developing therapies for ultra-rare pediatric orphan diseases. Prizm Therapeutics is focused on advancing innovation that improves human health and well-being . We have assembled a team of world class experts in the study and treatment of AHDS, drug development leaders, and business executives to advance SRW101 for AHDS. Our team is driven by science, knowledge, and compassion to provi … alth Research Institute’s topline by 3x in 4 years and established a innovation fund for the $3 billion health system. Founding director of Cancer Clinical Research Office at Hartford Healthcare Cancer Institute. Dr. Avancha received his PhD in Medicinal Chemistry from the University of South Florida. Vivek Kopparthi, MS Vivek Kopparthi is a healthcare innovator and entrepreneur with a deep passion for empathy-driven innovation. Vivek has 10+ years of management experience in … genetics. He is also the recipient of the Fred Conrad Koch Lifetime Achievement Award, the highest honor given by the Endocrine Society. Dr. Refetoff’s laboratory work focuses on identifying genetic errors that cause defects in thyroid hormone regulation, synthesis, transport and action. Dr. Refetoff has described several genetic diseases of the thyroid, including resistance to thyroid hormone (Refetoff’s syndrome). He has one of the largest referral centers for genetic thyro … ompleted his undergraduate and medical degrees at the University of Chicago and fellowship training in Endocrinology and Metabolism at the University of California, San Francisco (UCSF). He is certified in internal medicine and the subspecialty of endocrinology & metabolism. Dr. Noor also holds a Master’s Degree in clinical research from Vanderbilt University School of Medicine. Elliot Joseph Elliot Joseph most recently has served for 11 years as CEO of Hartford HealthCare (H … ces industry, and a member of the board of directors of the Johnny Mac Soldiers Fund which serves the families of our nation’s fallen service members. Mr. Pascoe served on active duty as a commissioned officer with the U.S. Army’s 24th Infantry Division with one combat tour in Iraq where he earned several awards and decorations including the Bron
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Israeli Companies at the GFI Forum SachsForum SachsForum EVENTS: Upcoming Events > 1st EHIS Forum 26th BEF Forum 10th NIF Forum Recent Events > 2nd OCIF > POST 2nd OCIF Participants > Attendees Investors Presenters Sponsors Supporters 19th ELSF > POST 19th ELSF Participants > Attendees Investors Presenters Exhibitors Sponsors Supporters 1st ENIF > POST 1st ENIF Participants > Attendees Investors Presenters Sponsors Supporters 9th NIF > POST 9th NIF Participants > Attendees Investors Presenters Sponsors Supporters 11th OIF > POST 11th OIF Participa … tly to cervical images, and collaborate with peers remotely. The EVA System has application for clinical colposcopy and forensic imaging. MobileODT is constantly evolving, adapting it’s products to a variety of clinical settings and is currently exploring the integration of AI for cancer detection. ​ https://www.mobileodt.com/ ​Nano Retina Nano-Retina is developing a miniature artificial retina to restore vision for people who are blind due to retinal degene … eutics system integrates the electronic head mounted device, a dedicated mobile application and a cloud database that gather and analyze data to optimize brain neuromodulation and provide individualized treatment. Future indications in the pipeline include ADHD and Insomnia. Serial entrepreneurs with proven success in the Neuromodulation space. https://www.neurolief.com/ ​Nuance Hearing Nuance Hearing designs, develops and markets breakthrough Selective Noise Cance … ding funds to see companies represented by them at the conference https://amoon.fund/portfolio/ https://www.arkinholdings.com/healthcare-investments/ https://www.gurnetpointcapital.com/investments https://israelbiotechfund.com/ http://www.orbimed.com/en/portfolio http://www.rainbowmd.com/our-companies/ Sachs Associates Switzerland AG ​ ​ Aeschenvorstadt 4 Basel | CH-4501 ​Switzerland ​ Sachs Associates Ltd. ​ ​ 3rd floor, 89-90 Paul Street
ExitValley Invest in the Start-up Nation Toggle navigation Invest Ayalon invest NEW Raise Capital About us עברית Login Sign Up City Transformer Is Now in Overfunding! Revolutionizing Urban Mobility City Transformer has developed a fully electric urban vehicle for city driving, car sharing and delivery services. Its patented shape-shifting platform lets the car narrow to a motorcycle footprint, to traffic and for parking or widen for stability. Find Out More & Invest 44,500 Investors In our community $113,280,000 Raised so far 156 Rounds Successfully funded News Exit Valley 16/06/2026 Caps Med … The development is based on scientific research and a team that includes Nobel Prize laureates. The funding will be used to advance further development, with the goal of delivering a genuine medical solution 17 Days to go $120,000 Minimum investment 751% of funding target Angel Investment Pharma & Biopharma • Overfunding - Over 100% Anti CLABSI A Revolutionary Medical Patch – 360° Protection Against IV Infections In collaboration with Sheba Medical Center and … eurs Raise Capital Scouters Legal Info Terms of Use Privacy Policy Risk Warning Proposal coordinator license Accessibility statement The financing rounds, made through the ExitValley platform, are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) of the Israeli Securities Law - 1968. Under this model, the disclosure of detailed information on the company and information about the investment in each roun
Hi my friend! I hope you are... - Betalin Therapeutics Inc Facebook Log In Betalin Therapeutics Inc's Post Betalin Therapeutics Inc January 5, 2020 · Shared with Public Hi my friend! I hope you are doing well so far in 2020! I am very pleased to announce that Betalin Therapeutics was selected as the second most innovative start up from the past decade by “The Start-up Nation!" We competed with very high level companies and are ecstatic to receive this recognition. The others successful nominees were Beresheet (The spacecraft to the Moon) who got the first position, Mobileye (company
Paz Capital - IVC Data & Insights --> --> Recently Updated Analytics Products & Solutions Reports & Insights Free Trial Buy Log In Remember Me Forgot my password Free Trial Free Content Please wait Processing your login information Cancel You're about to hit a 'session timeout' in 5 minutes. Are you still actively using IVC-Online website? Search Go Advanced Search Advanced Search Did you know? Search at IVC-Online works best with strings or words of 3 letters or more. Please try again Paz Capital www.paz-capital.com Famil
Cell Therapy | Breakthrough T1D --> Skip to content Welcome to the website of Breakthrough T1D ® Canada EN FR Breakthrough T1D About Breakthrough T1D Who we are We are Breakthrough T1D Our story Breakthrough T1D worldwide Contact us Our people Executive team Board of Directors Join our team Financials Where your money goes Annual impact report and financial statements News and media News + media Breakthrough T1D blog Our impact Research Curing T1D Improving lives Breakthrough T1D funded projects Clinical trials Grant opportunities TrialNet Screening Program Mission Project ACT Framework for Di … ociated with T1D. Breakthrough T1D is investing in this approach via a research grant to Dr. James Shapiro at the University of Alberta to address these scientifically important questions. However, Breakthrough T1D’s global research strategy in the area of cell therapies is focused on allogenic cells (meaning derived from another person’s cells) to create islet products that can be used to treat large numbers of people with T1D, rather than pursuing personalized therapi … ) was awarded a Breakthrough T1D Industry Discovery and Development Partnership grant in 2023 to advance their research into polymers and hydrogels (a material similar to what is used for contact lenses) that can provide an immunoprotective coating to islet-like cells. Here is an abbreviated list of other companies around the world at pre-clinical stages of T1D cell therapy development (note that this list is not exhaustive, and information is current at time of writing): Eli … eta cells from stem cells in the laboratory. 7 Breakthrough T1D funds a 10-year grant to Douglas Melton, Ph.D., for almost $1.4 million, to make beta cells from stem cells. 2001 Breakthrough T1D and the National Institutes of Health (NIH) co-found the Immune Tolerance Network (ITN), a seven-year, $144 million project, to conduct clinical trials aimed at inducing immune tolerance in the context of transplantation, autoimmune diseases, asthma, or allergies. The first major tria … rived beta cells into curative therapies for T1D. In 2017, the Breakthrough T1D Fund makes a catalytic investment in Semma to bridge the company to its next large venture round. 2019 Vertex Pharmaceuticals acquires Semma Therapeutics for nearly $1 billion. — ViaCyte reports on its VC-01™ therapy using stem cell-derived islet-like cells. Pre
Biomed 24/7 Buzz Startups VC AI Innovation Opinions Events Promising Startups 2026 2026 VC Survey Boarding Pass CTalk BiblioTech Corporate Appointments Tech Gateways @Finance Ctech Testimonials Projects About Newsletter Contact us Facebook Twitter ACCESSIBILITY by Homepage Biomed Tags search HOME 24/7 buzz STARTUPS VC AI Innovation OPINIONS EVENTS Projects ABOUT teram of use Privacy Policy NEWSLETTER SEARCH CONTACT US ACCESSIBILITY 24/7 Headlines 16:00 Immunai signs up to $15 million research pact with Boehringer Ingelheim 15:20 AI's “English-washing” problem 15:01 From Israel’s mos … lion investment in MediWound 05.02.23 | Golan Hazani Cohen's Point72 hedge fund invested $15 million in the round in what is believed to be the billionaire’s first investment in an Israeli company Betalin Therapeutics receives EU equity investment for its alternative insulin therapy 21.07.21 | James Spiro The Biomed startup seeks to eliminate the need for insulin injections and glucose testing Shuki Gleitman's GIBF raising $300 million in China for second biotech fu … otech fund 31.05.21 | Golan Hazani The Guangzhou Sino-Israel Biotech Investment Fund (GIBF) focuses on life science investments and cooperates with leading Guangzhou organizations to bring Israeli biotech firms to the massive Chinese metropolitan Moderna’s resigning CMO says he achieved what he cared about 25.02.21 | Sophie Shulman Tal Zaks: I never imagined that I’d develop a vaccine for the worst pandemic of our times Covid-19 was one of the biomed industry’s finest hours, … w the coronavirus vaccines showcased the depth of new technology Israel’s aMoon fund saw a 15-fold return on its investment in Seer 09.12.20 | Sophie Shulman aMoon invested in the U.S. biomed company when it was valued at $228 million- after a Nasdaq IPO, its value ballooned to $3.5 billion Biomed at the focus of new Israel-UAE business cooperation 25.10.20 | CTech New cross-business initiative is led by Tel-Aviv based consultancy firm Kamir Strategy and UAE-based PR firm Cos … n Biomed Company Kamada 22.01.20 | Tzally Greenberg Israel-based private equity fund FIMI became the largest shareholder in Nasdaq and Tel Aviv-listed Kamada in November FIMI Becomes Biggest Shareholder in Biomed Company Kamada 24.11.19 | Golan Hazani and Tzally Greenberg Nasdaq and Tel Aviv-listed Kamada develops protein-based pharmaceuticals fo
Israel's Betalin Therapeutics plans IPO to fund diabetes trials IN FOCUS ✕ Home News Analysis Agro-Forestry Art & Culture Technology Economy & Business Education Energy & Extractives Politics Law & Governance Health Science & Environment Social & Gender Sports Transport Urban Development WASH Research LogIn/SignUp Israel's Betalin Therapeutics plans IPO to fund diabetes trials The system mimics the function of a healthy pancreas by secreting insulin and making daily injections unnecessary, said CEO Nikolai Kunicher. The company, which is funded by private inve … al public offering that will value the biotech firm between $150-170 million to fund trials for its diabetes treatment, the company's chief executive said on Wednesday. Betalin is developing an artificial micro-pancreas that is implanted in the thigh of diabetics to help control the level of sugar in their blood. The system mimics the function of a healthy pancreas by secreting insulin and making daily injections unnecessary, said CEO Nikolai Kunicher. The company, which is f
Everly Bio is embarking on a transformative journey in reproductive medicine with substantial backing from the Rimon Investment Fund and Yissum at The Hebrew University of Jerusalem. Dr. Yael Heifetz and her team's collaborative efforts, including partnerships with VLX Ventures and prominent academic institutions such as Tel Aviv University and Hadassah Medical Center, signify a significant stride in bridging the gap between academic research and practical healthcare solutions. The company's pioneering molecular platform offers personalized fertility treatment plans, promising to enh … tility challenges worldwide. The strategic investment from Yissum and the Rimon Fund not only validates Everly Bio's innovative technology but also accelerates its global impact in revolutionizing fertility care. Driven by a fervor for innovation and a dedication to improving the lives of those affected by infertility, Everly Bio is poised to usher in a new era of accessible and effective fertility treatments. Through their collaborative efforts and cutting-edge approach … ney in reproductive medicine with substantial backing from the Rimon Investment Fund and Yissum at The Hebrew University of Jerusalem. Dr. Yael Heifetz and her team's collaborative efforts, including partnerships with VLX Ventures and prominent academic institutions such as Tel Aviv University and Hadassah Medical Center , signify a significant stride in bridging the gap between academic research and practical healthcare solutions. The company's pioneering molecular … tility challenges worldwide. The strategic investment from Yissum and the Rimon Fund not only validates Everly Bio's innovative technology but also accelerates its global impact in revolutionizing fertility care. Driven by a fervor for innovation and a dedication to improving the lives of those affected by infertility, Everly Bio is poised to usher in a new era of accessible and effective fertility treatments. Through their collaborative efforts and cutting-edge approach
EU fund invests in Israeli firm that develops diabetes solutions | The Jerusalem Post CONFERENCES ISRAEL NEWS WORLD NEWS MIDDLE EAST BUSINESS & INNOVATION DEFENSE & TECH OPINION JP STORE Login Login Subscribe JPOST DIGITAL LIBRARY HOME PAGE THE JERUSALEM REPORT DEFENSE & TECH OPINION BUSINESS & INNOVATION JERUSALEM POST EN ESPANOL REAL ESTATE LISTINGS ALIYAH JERUSALEM POST CONFERENCE PREMIUM JP STORE Categories ISRAEL NEWS WORLD NEWS MIDDLE EAST US POLITICS DIASPORA OPINION PODCAST JUDAISM KABBALAH CHRISTIAN WORLD HEALTH & WELLNESS SCIENCE LAW ARCHAEOLOGY OMG ENVIRONMENT &a … UT US Jerusalem Post / Business & Innovation / Tech & Start-ups EU tech fund invests in Israeli firm that develops diabetes solutions The investment is intended to fund human trials of a biological pancreas that produces insulin independently in the body and renders further injections unnecessary. Follow us on Google The pancreas created by Israeli company Betalin Therapeutics. ( photo credit : YOSSI ZAMIR ) By JERUSALEM POST STAFF JANUARY 26, 2022 13:24 Updated : JAN … 22 13:24 Updated : JANUARY 27, 2022 15:42 The European Innovation Council (EIC) Fund has decided to make a direct equity investment in Israeli company Betalin Therapeutics in the amount of €500,000. The investment is intended to fund human trials of a biological pancreas that produces insulin independently in the body and renders further injections unnecessary. Shuki Hershcovich (credit: Courtesy) The European fund will appoint an observer to Betalin’s Board of Directors in o … cs to further develop its revolutionary therapy for diabetes treatment. The EIC Fund is thrilled to support unique technologies aiming to have a global impact improving patient’s life conditions” said José Fernando Figueiredo, member of the Investment Committee of the EIC Fund. The new investment follows €3.6 million in grants Betalin Therapeutics received last year from the EU’s prestigious Horizon 2020 R&D program. To date, Betalin Therapeutics has raised NIS 45 million … e proud to be among the first technology companies that the European Investment Fund has decided to invest in,” said Betalin Chairman Shuki Hershcovich. “The fund’s investment is indicative of the EU’s confidence in the technology that Betalin is developing and its ability to bring a solution to many people suffering from the disease. The money r
Insulin replacement co Betalin Therapeutics raises $2.5m - Globes " /> " /> " /> " /> search G Front News Comment Features MARKET ECONOMY ENERGY HEALTHCARE TECH REAL ESTATE START UPS AEROSPACE & DEFENSE CHEMICALS & PLASTICS FINANCIAL SERVICES MERGERS & ACQUISITIONS POLITICS TELECOMS, MEDIA & MARKETING TOURISM TRANSPORT & INFRASTRUCTURE Front > News Insulin replacement co Betalin Therapeutics raises $2.5m Diabetes Photo: Shutterstock Enlight raises $2.6b for Arizona solar project Enlight raises $2.6b for Arizona solar project 24 Apr, 2019 12:13 Globes correspondent The Jerusalem-based compan … plementation. RELATED ARTICLES Betalin Therapeutics wins best biopharma startup award Israeli startup aims to end insulin injections Founded in 2015, Betalin's technology was developed by Prof. Eduardo Mitrani of the Hebrew University of Jerusalem's Faculty of Science. The theory behind this technology is that cells need to be in contact with a supportive tissue, a kind of scaffold which will mimic the extracellular matrix surrounding the cells in our body. Prof Mitrani expla … > Diabetes Photo: Shutterstock Betalin Therapeutics wins best biopharma startup award ��� ���� >> Globes correspondent Israeli startup aims to end insulin injections ��� ���� >> Shiri Dover Front News Comment Features Market Newsletters Globes Conferences RSS Israel Resources ����� Advertising Terms of Use Privacy Policy About Support Powered by UI & Design By Application delivery by � Globes. All rights reserved. Twitter Facebook Linke
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
BETALIN – Liberating from Insulin Dependency Skip to content Home About Benefits Video Recognition Team Contact Home About Benefits Video Recognition Team Contact MICRO PANCREAS TECHNOLOGY Betalin is developing a micro-pancreas to liberate hundreds of millions of diabetic patients from their daily insulin dependency. The micro-pancreas responds to the patient’s blood glucose levels by releasing regulated therapeutic levels of insulin. Innovation Our innovation combines state-of-the art stem cell technology with a breakthrough in tissue engineering to create a fully functional engineered … engineers, clinical experts, and a advisory board whose members include a Nobel prize winner and the President-Elect of the International Diabetes Federation. The company is led by: Avi Geffen Chairman Over 30 years of experience in managing business activities, initiating and managing investments, and managing private and public companies. Currently serves as the CEO of GRE investment bank Ltd, an investment banking group, as well as the CEO of Unic-Tech LP, an investment fu … her PhD in cell biology from the Technion, where she completed her postdoctoral fellowship. She also holds an MA in patent law from the University of Haifa. Prof. Arieh Warshel (Israel) Nobel Prize winner in chemistry Prof. Peter Schwarz (Germany) President-Elect, Intern. Diabetes Federation Prof. Stefan Bornstein (Germany) Director, Univ. Hospital Carl Gustav Carus Prof. Lonnie Shea (USA) Biomed Eng., Univ. of Michigan Prof. James Shaw (UK) Regen. Medicine for Diabetes, Ne